These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 15149155)
1. Induction of a multifactorial resistance phenotype by high paclitaxel selective pressure in a human ovarian carcinoma cell line. Violini S; D'Ascenzo S; Bagnoli M ; Millimaggi D; Miotti S; Canevari S; Pavan A; Dolo V J Exp Clin Cancer Res; 2004 Mar; 23(1):83-91. PubMed ID: 15149155 [TBL] [Abstract][Full Text] [Related]
2. Lack of ceramide generation and altered sphingolipid composition are associated with drug resistance in human ovarian carcinoma cells. Prinetti A; Millimaggi D; D'Ascenzo S; Clarkson M; Bettiga A; Chigorno V; Sonnino S; Pavan A; Dolo V Biochem J; 2006 Apr; 395(2):311-8. PubMed ID: 16356169 [TBL] [Abstract][Full Text] [Related]
3. Activity of docetaxel in paclitaxel-resistant ovarian cancer cells. Sato S; Kigawa J; Kanamori Y; Itamochi H; Oishi T; Shimada M; Iba T; Naniwa J; Uegaki K; Terakawa N Cancer Chemother Pharmacol; 2004 Mar; 53(3):247-52. PubMed ID: 14610615 [TBL] [Abstract][Full Text] [Related]
4. Intrinsic chemotherapy resistance to the tubulin-binding antimitotic agents in renal cell carcinoma. Ferguson RE; Jackson SM; Stanley AJ; Joyce AD; Harnden P; Morrison EE; Patel PM; Phillips RM; Selby PJ; Banks RE Int J Cancer; 2005 May; 115(1):155-63. PubMed ID: 15645438 [TBL] [Abstract][Full Text] [Related]
5. Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary. Itamochi H; Kigawa J; Sultana H; Iba T; Akeshima R; Kamazawa S; Kanamori Y; Terakawa N Jpn J Cancer Res; 2002 Jun; 93(6):723-8. PubMed ID: 12079522 [TBL] [Abstract][Full Text] [Related]
6. Tubulin from paclitaxel-resistant cells as a probe for novel antimicrotubule agents. Sackett DL; Giannakakou P; Poruchynsky M; Fojo A Cancer Chemother Pharmacol; 1997; 40(3):228-32. PubMed ID: 9219506 [TBL] [Abstract][Full Text] [Related]
7. Overexpression of IL-6 but not IL-8 increases paclitaxel resistance of U-2OS human osteosarcoma cells. Duan Z; Lamendola DE; Penson RT; Kronish KM; Seiden MV Cytokine; 2002 Mar; 17(5):234-42. PubMed ID: 12027404 [TBL] [Abstract][Full Text] [Related]
8. Mechanisms of paclitaxel-induced apoptosis in an ovarian cancer cell line and its paclitaxel-resistant clone. Sugimura M; Sagae S; Ishioka S; Nishioka Y; Tsukada K; Kudo R Oncology; 2004; 66(1):53-61. PubMed ID: 15031599 [TBL] [Abstract][Full Text] [Related]
9. Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents. Nicoletti MI; Valoti G; Giannakakou P; Zhan Z; Kim JH; Lucchini V; Landoni F; Mayo JG; Giavazzi R; Fojo T Clin Cancer Res; 2001 Sep; 7(9):2912-22. PubMed ID: 11555610 [TBL] [Abstract][Full Text] [Related]
10. ClC-3 promotes paclitaxel resistance via modulating tubulins polymerization in ovarian cancer cells. Feng J; Peng Z; Gao L; Yang X; Sun Z; Hou X; Li E; Zhu L; Yang H Biomed Pharmacother; 2021 Jun; 138():111407. PubMed ID: 33765585 [TBL] [Abstract][Full Text] [Related]
11. Multiplicity of acquired cross-resistance in paclitaxel-resistant cancer cells is associated with feedback control of TUBB3 via FOXO3a-mediated ABCB1 regulation. Aldonza MB; Hong JY; Alinsug MV; Song J; Lee SK Oncotarget; 2016 Jun; 7(23):34395-419. PubMed ID: 27284014 [TBL] [Abstract][Full Text] [Related]
12. Impact of intraperitoneal, sustained delivery of paclitaxel on the expression of P-glycoprotein in ovarian tumors. Ho EA; Soo PL; Allen C; Piquette-Miller M J Control Release; 2007 Jan; 117(1):20-7. PubMed ID: 17113177 [TBL] [Abstract][Full Text] [Related]
13. Increased levels of tyrosinated alpha-, beta(III)-, and beta(IV)-tubulin isotypes in paclitaxel-resistant MCF-7 breast cancer cells. Banerjee A Biochem Biophys Res Commun; 2002 Apr; 293(1):598-601. PubMed ID: 12054644 [TBL] [Abstract][Full Text] [Related]
14. Altered levels and regulation of stathmin in paclitaxel-resistant ovarian cancer cells. Balachandran R; Welsh MJ; Day BW Oncogene; 2003 Dec; 22(55):8924-30. PubMed ID: 14654788 [TBL] [Abstract][Full Text] [Related]
15. Suberoylanilide hydroxamic acid partly reverses resistance to paclitaxel in human ovarian cancer cell lines. Angelucci A; Mari M; Millimaggi D; Giusti I; Carta G; Bologna M; Dolo V Gynecol Oncol; 2010 Dec; 119(3):557-63. PubMed ID: 20825984 [TBL] [Abstract][Full Text] [Related]
16. Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). Dumontet C; Duran GE; Steger KA; Beketic-Oreskovic L; Sikic BI Cancer Res; 1996 Mar; 56(5):1091-7. PubMed ID: 8640766 [TBL] [Abstract][Full Text] [Related]
17. Establishment and characterization of a paclitaxel‑resistant human esophageal carcinoma cell line. Wang C; Guo LB; Ma JY; Li YM; Liu HM Int J Oncol; 2013 Nov; 43(5):1607-17. PubMed ID: 24002547 [TBL] [Abstract][Full Text] [Related]
18. Cross-resistance to the synthetic retinoid CD437 in a paclitaxel-resistant human ovarian carcinoma cell line is independent of the overexpression of retinoic acid receptor-gamma. Kumar A; Soprano DR; Parekh HK Cancer Res; 2001 Oct; 61(20):7552-5. PubMed ID: 11606393 [TBL] [Abstract][Full Text] [Related]
19. Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer. Giannakakou P; Poy G; Zhan Z; Knutsen T; Blagosklonny MV; Fojo T Oncogene; 2000 Jun; 19(27):3078-85. PubMed ID: 10871860 [TBL] [Abstract][Full Text] [Related]
20. Potent inhibition of tubulin polymerisation and proliferation of paclitaxel-resistant 1A9PTX22 human ovarian cancer cells by albendazole. Chu SW; Badar S; Morris DL; Pourgholami MH Anticancer Res; 2009 Oct; 29(10):3791-6. PubMed ID: 19846910 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]